MP09-12 BETHANECHOL: IS IT STILL BEING PRESCRIBED FOR BLADDER DYSFUNCTION IN WOMEN?

Abstract

You have accessJournal of UrologyBladder & Urethra: Anatomy, Physiology & Pharmacology I1 Apr 2018MP09-12 BETHANECHOL: IS IT STILL BEING PRESCRIBED FOR BLADDER DYSFUNCTION IN WOMEN? Shivani Gaitonde, Rena D Malik, Gary E Lemack, and Philippe E Zimmern Shivani GaitondeShivani Gaitonde More articles by this author , Rena D MalikRena D Malik More articles by this author , Gary E LemackGary E Lemack More articles by this author , and Philippe E ZimmernPhilippe E Zimmern More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.338AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Few medical treatment options exist in the management of detrusor underactivity or urinary retention in women. Bethanechol, a cholinergic agonist may improve detrusor contractility in these conditions; however, its clinical efficacy is limited. We sought to examine the patterns of bethanechol use by physicians in an ambulatory care setting using a national database. METHODS The National Ambulatory Medical Care Survey (NAMCS) database was queried for a nationwide sample of patient visits to office-based physicians from 2003-2013. Visits were included for women aged 18 years or older with diagnosed lower urinary tract symptoms (LUTS), neurogenic bladder, or urinary retention based on ICD-9-CM codes. Visits in which bethanechol was prescribed were analyzed utilizing descriptive statistics. Survey analysis procedures were used taking into account the clustered nature of the sample. Sampling weights were adjusted for non-responders to yield an unbiased national estimate of ambulatory care visits. RESULTS Out of a weighted sample of 17,321,630 included patient visits, 132,281 (0.8%) visits included a prescription for bethanechol. Patients prescribed bethanechol had a mean age of 62.3±2.1 and were predominantly Caucasian (67%) followed by African American (18%). The primary diagnoses associated with bethanechol were atony of bladder (35%), urinary retention (20%), neurogenic bladder (18%), urinary incontinence (16%), and incomplete bladder emptying (10%). Visits were primarily for chronic conditions (63%). Bethanechol was most often prescribed as a continued medication (79%) and the prescribers were urologists (92%) followed by internal medicine clinicians (8%). CONCLUSIONS Despite its debated clinical utility, bethanechol continues to be used in a small percentage of women primarily for detrusor atony, urinary retention and incomplete bladder emptying. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e110-e111 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Shivani Gaitonde More articles by this author Rena D Malik More articles by this author Gary E Lemack More articles by this author Philippe E Zimmern More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...